Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $1.7 billion.

  • Rxo's Total Liabilities fell 366.26% to $1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year decrease of 366.26%. This contributed to the annual value of $1.7 billion for FY2025, which is 366.26% down from last year.
  • Per Rxo's latest filing, its Total Liabilities stood at $1.7 billion for Q4 2025, which was down 366.26% from $1.6 billion recorded in Q3 2025.
  • Rxo's 5-year Total Liabilities high stood at $1.8 billion for Q4 2024, and its period low was $998.0 million during Q4 2021.
  • Moreover, its 5-year median value for Total Liabilities was $1.4 billion (2023), whereas its average is $1.4 billion.
  • Within the past 5 years, the most significant YoY rise in Rxo's Total Liabilities was 4638.51% (2024), while the steepest drop was 1507.33% (2024).
  • Rxo's Total Liabilities (Quarter) stood at $998.0 million in 2021, then skyrocketed by 44.69% to $1.4 billion in 2022, then dropped by 14.75% to $1.2 billion in 2023, then surged by 46.39% to $1.8 billion in 2024, then dropped by 3.66% to $1.7 billion in 2025.
  • Its Total Liabilities stands at $1.7 billion for Q4 2025, versus $1.6 billion for Q3 2025 and $1.6 billion for Q2 2025.